Comparing Eye Pressure Using Maximal Tolerated Local Therapy or Systemic Acetazolamide

NCT ID: NCT01274039

Last Updated: 2013-04-15

Basic Information

• Recruitment Status: COMPLETED
• Study Classification: OBSERVATIONAL
• Study Start Date: 2009-02-28
• Study Completion Date: 2012-02-29

Brief Summary

Local therapy for glaucoma is known to induce a conjunctival inflammation. Because of this, trabeculectomy is more likely to fail. The investigators exchange the local therapy by systemic therapy using acetazolamide and measure the eye pressure using local therapy and systemic therapy using acetazolamide. The investigators suspect an elevated eye pressure using acetazolamide compared to local therapy. In summary acetazolamide could be a better choice in reference to conjunctival inflammation, but a worse choice in reference to controlling eye pressure.

Conditions

Control of Elevated Eye Pressure by Local and Systemic Therapy

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Study Groups

Patient with a trabeculectomy planed

Acetazolamide for glaucoma patients to lower eye pressure

Intervention Type: DRUG

Acetazolamide tablets 3 times daily for 3 to 4 weeks

Interventions

Acetazolamide for glaucoma patients to lower eye pressure

Acetazolamide tablets 3 times daily for 3 to 4 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with uncontrolled intraocular eye pressure
• Patients with planed trabeculectomy in 3 to 4 weeks

• Patients with known intolerance to acetazolamide

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Cologne

OTHER

Sponsor Role: lead

Locations

University of Cologne

Cologne, , Germany

Countries

Germany

Other Identifiers

AcetazolamideTrialCologne

Identifier Type: -

Identifier Source: org_study_id